- Home
- VALU vs NNNN Comparison
VALU vs NNNN Comparison
Compare VALU & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VALU
- NNNN
- Stock Information
- Founded
- VALU 1931
- NNNN 2021
- Country
- VALU United States
- NNNN Germany
- Employees
- VALU N/A
- NNNN N/A
- Industry
- VALU Investment Managers
- NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- VALU Finance
- NNNN Health Care
- Exchange
- VALU Nasdaq
- NNNN Nasdaq
- Market Cap
- VALU 358.0M
- NNNN 369.6M
- IPO Year
- VALU N/A
- NNNN 2025
- Fundamental
- Price
- VALU $37.78
- NNNN $53.00
- Analyst Decision
- VALU
- NNNN
- Analyst Count
- VALU 0
- NNNN 0
- Target Price
- VALU N/A
- NNNN N/A
- AVG Volume (30 Days)
- VALU 2.4K
- NNNN 235.4K
- Earning Date
- VALU 07-25-2025
- NNNN 01-01-0001
- Dividend Yield
- VALU 3.26%
- NNNN N/A
- EPS Growth
- VALU 17.96
- NNNN N/A
- EPS
- VALU 2.28
- NNNN 0.06
- Revenue
- VALU $35,695,000.00
- NNNN $8,185,146.00
- Revenue This Year
- VALU N/A
- NNNN N/A
- Revenue Next Year
- VALU N/A
- NNNN N/A
- P/E Ratio
- VALU $16.54
- NNNN $898.97
- Revenue Growth
- VALU N/A
- NNNN 21.95
- 52 Week Low
- VALU $32.94
- NNNN $5.18
- 52 Week High
- VALU $57.68
- NNNN $55.65
- Technical
- Relative Strength Index (RSI)
- VALU 45.67
- NNNN N/A
- Support Level
- VALU $38.00
- NNNN N/A
- Resistance Level
- VALU $39.73
- NNNN N/A
- Average True Range (ATR)
- VALU 0.67
- NNNN 0.00
- MACD
- VALU -0.00
- NNNN 0.00
- Stochastic Oscillator
- VALU 1.17
- NNNN 0.00
About VALU Value Line Inc.
Value Line Inc is a U.S based company. It produces investment periodicals based on underlying research and making available copyright data, including ranking system and other information, to third parties under written agreements for use in third-party managed and marketed investment products and for other purposes. The company markets under brands including Value Line, the Value Line logo, The Value Line Investment Survey, Smart Research, Smarter Investing and a trusted name in Investment Research. Its only operating segment being Publishing.
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.